Greenwich LifeSciences, Inc. GLSI
Set alert
At close
Pre-market · Nov 2, 8:18 AM ET
- YTD
- -17.13%
- 1 year
- +89.45%
- Open
- 18.47
- Prev close
- 19.00
- Mkt cap
- 255.55M
- Vol
- 174.65K
- Avg vol
- 127.98K
- EPS
- -1.53
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 17.08
- High
- 18.77
- Forward P/E
- -14.83
- Beta
- 3.32
- Short ratio
- 21.41
- Inst. own
- 8.70%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Aug 14, 2024
- 50-d avg
- 13.57
- 200-d avg
- 14.65
- 1y target
- 38.00
News
-
2 months ago benzinga.com
Greenwich LifeSciences Extends 100% Insider Share Lock‑Up To January 31, 2027
Greenwich LifeSciences, Inc. (NASDAQ:GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01, which is evaluating Fast Track designated…
-
3 months ago benzinga.com
HC Wainwright & Co. Maintains Buy on Greenwich LifeSciences, Raises Price Target to $69
HC Wainwright & Co. analyst Yi Chen maintains Greenwich LifeSciences (NASDAQ:GLSI) with a Buy and raises the price target from $50 to $69.
-
3 months ago benzinga.com
Greenwich LifeSciences Expects Q2 Cash Burn To Be ~$2M, Down From $4.7M In Q1, With Cash Balance Of ~$8.9M As Of June And Expected Burn Rate Of $2-4M Per Quarter Going Forward
FLAMINGO-01 Data Safety Monitoring Board (DSMB)The FLAMINGO-01 DSMB met in May 2026 and recommended the study continue as is without modification.FLAMINGO-01 Steering Committee Clinical StrategyOn…
-
3 months ago benzinga.com
Greenwich LifeSciences Receives Approval From European Medicines Agency To Combine HLA-A*02, Non-HLA-A*02 Participants In Europe
Greenwich LifeSciences, Inc. (NASDAQ:GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01, which is evaluating GLSI-100, an…
-
3 months ago benzinga.com
Greenwich LifeSciences Receives EMA Approval To Use Commercially Manufactured GP2 In Its FLAMINGO-01 Phase III Clinical Trial
All European and US Sites to Treat Patients with Commercially Manufactured GP2The Company previously announced that the first three commercial lots of GP2 active ingredient were manufactured in 2023…
-
5 months ago benzinga.com
Greenwich LifeSciences Q4 EPS $(0.58) Misses $(0.31) Estimate
Greenwich LifeSciences (NASDAQ:GLSI) reported quarterly losses of $(0.58) per share which missed the analyst consensus estimate of $(0.31) by 87.1 percent. This is a 4.92 percent increase over losses…
-
5 months ago benzinga.com
Greenwich LifeSciences Announces Published Abstract And Poster On Its Phase III FLAMINGO-01 Trial For GLSI-100 To Prevent Breast Cancer Recurrences From The ASCO Annual Meeting 2026
from the ASCO Annual Meeting 2026.The abstract is shown below and the poster being presented today can be seen and downloaded at the bottom of the Phase III clinical trial tab on the Company's…
-
5 months ago benzinga.com
Greenwich LifeSciences Reports Progress in Late-Stage Breast Cancer Immunotherapy Trial
Greenwich LifeSciences, Inc. (NASDAQ:GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01, which is evaluating Fast Track designated…
-
5 months ago benzinga.com
Greenwich LifeSciences Receives Nasdaq Noncompliance Notice
Greenwich LifeSciences, Inc. (NASDAQ:GLSI) ("Greenwich" or the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01, which is evaluating Fast…
6 months ago benzinga.com
Why Kyverna Therapeutics Shares Are Trading Higher By Over 25%; Here Are 20 Stocks Moving Premarket
Kyverna Therapeutics Inc (NASDAQ: KYTX) shares rose 25.8% in pre-market trading after positive trial results for miv-cel. Other gainers include HCAI, ELPW, and ALP.
-
6 months ago benzinga.com
Greenwich LifeSciences Reports 70%–80% Drop In Cancer Recurrence In Early Trial Data
Greenwich LifeSciences, Inc. (NASDAQ:GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01, which is evaluating Fast Track designated…
-
6 months ago benzinga.com
Greenwich LifeSciences Says Breast Cancer Therapy Could Double Patient Reach With New Patent Claims
Greenwich LifeSciences, Inc. (NASDAQ:GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01, which is evaluating Fast Track designated…
-
7 months ago benzinga.com
Greenwich LifeSciences Expands Breast Cancer Trial Across Major US Cancer Centers, Launches New Study Sites To Advance Cancer Recurrence Therapy
Greenwich LifeSciences, Inc. (NASDAQ:GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01, which is evaluating Fast Track designated…
-
7 months ago benzinga.com
Greenwich Lifesciences' Preliminary Update Shows A Continued Reduction In The Recurrence Rate In The Fully Enrolled, 250-patient, Open-label Non-HLA-A*02 Arm Of FLAMINGO-01
Greenwich LifeSciences, Inc. (NASDAQ:GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01, which is evaluating GLSI-100, an…
-
7 months ago benzinga.com
Greenwich LifeSciences Says FDA Approves The First Commercial Lot Of GP2 Vials For Use In FLAMINGO-01 Study In U.S.
STAFFORD, Texas, March 16, 2026 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (NASDAQ:GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial,…
-
9 months ago benzinga.com
Greenwich LifeSciences Says Cash on Hand Can Cover 2026 as Breast Cancer Trial Advances
Greenwich LifeSciences, Inc. (NASDAQ:GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01, which is evaluating Fast Track designated…
9 months ago benzinga.com
Sarepta Therapeutics, Lands' End, USA Rare Earth, CoreWeave And Other Big Stocks Moving Higher On Monday
Sarepta Therapeutics, Lands' End, USA Rare Earth, CoreWeave And Other Big Stocks Moving Higher On Monday
9 months ago benzinga.com
Greenwich LifeSciences Stock Jumps After FDA Update
Greenwich LifeSciences, Inc. (NASDAQ:GLSI) shares are trading higher after the company announced the Food and Drug Administration approved the use of its first commercially manufactured GP2 lot for…
-
9 months ago benzinga.com
Market-Moving News for January 22nd
BABA: 5% | Alibaba shares are trading higher on Bloomberg report of company moving toward IPO of its in-house AI chipmaking unit, T-Head. GLSI: 65% | Greenwich LifeSciences Says FDA Clears First…
9 months ago benzinga.com
12 Health Care Stocks Moving In Thursday's Pre-Market Session
12 Health Care Stocks Moving In Thursday's Pre-Market Session
-
9 months ago benzinga.com
Greenwich LifeSciences Says FDA Clears First Commercial GP2 Lot for Phase III Breast Cancer Trial
Greenwich LifeSciences, Inc. (NASDAQ:GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01, which is evaluating GLSI-100, an…
10 months ago benzinga.com
Why OceanFirst Financial Shares Are Trading Lower By Around 7%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Why OceanFirst Financial Shares Are Trading Lower By Around 7%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
10 months ago benzinga.com
CapsoVision, ACM Research And Other Big Stocks Moving Higher On Tuesday
CapsoVision, ACM Research And Other Big Stocks Moving Higher On Tuesday
-
10 months ago benzinga.com
HC Wainwright & Co. Maintains Buy on Greenwich LifeSciences, Raises Price Target to $50
HC Wainwright & Co. analyst Yi Chen maintains Greenwich LifeSciences (NASDAQ:GLSI) with a Buy and raises the price target from $39 to $50.
10 months ago benzinga.com
What's Going On With Greenwich LifeSciences Stock Monday?
Greenwich LifeSciences shares are trading higher Monday after the company announced it extended its lock-up period to Sept. 30, 2026.
10 months ago benzinga.com
Why Ultragenyx Pharmaceutical Shares Are Trading Lower By Around 42%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Why Ultragenyx Pharmaceutical Shares Are Trading Lower By Around 42%? Here Are Other Stocks Moving In Monday's Mid-Day Session
-
10 months ago benzinga.com
12 Health Care Stocks Moving In Monday's Intraday Session
12 Health Care Stocks Moving In Monday's Intraday Session
10 months ago benzinga.com
12 Health Care Stocks Moving In Friday's After-Market Session
12 Health Care Stocks Moving In Friday's After-Market Session
10 months ago benzinga.com
Why Aptevo Therapeutics Shares Are Trading Lower By Around 38%? Here Are Other Stocks Moving In Friday's Mid-Day Session
Why Aptevo Therapeutics Shares Are Trading Lower By Around 38%? Here Are Other Stocks Moving In Friday's Mid-Day Session
-
10 months ago benzinga.com
12 Health Care Stocks Moving In Friday's Intraday Session
12 Health Care Stocks Moving In Friday's Intraday Session
10 months ago benzinga.com
What's Going On With Greenwich LifeSciences Friday?
Greenwich LifeSciences stock hits a new 52-week high! Discover how Greenwich LifeSciences is streamlining its Phase 3 FLAMINGO-01 trial.
10 months ago benzinga.com
Why Is Greenwich LifeSciences Stock Surging After Data From Breast Cancer Vaccine?
Greenwich LifeSciences stock rose after Phase 3 data showed GLSI-100 cut breast cancer recurrence rates by about 80% in new patients.
-
10 months ago benzinga.com
12 Health Care Stocks Moving In Monday's Pre-Market Session
12 Health Care Stocks Moving In Monday's Pre-Market Session
-
10 months ago benzinga.com
Greenwich LifeSciences Reports Early FLAMINGO-01 Results Showing 80% Reduction In Cancer Recurrences
A preliminary analysis of recurrence rates by two methods to estimate the reduction in recurrence rate shows an approximately 80% reduction in recurrence rate in the fully enrolled, 250 patient…
-
10 months ago benzinga.com
Greenwich Lifesciences Completed Enrollment In Open-Label HLA-A*02 Arm of FLAMINGO-01 Phase 3 Trial Of GLSI-100, An Immunotherapy To Prevent Breast Cancer Recurrences
In the double-blinded arms of the Phase III trial, approximately 500 HLA-A*02 patients are currently planned to be randomized to GLSI-100 or placebo, and up to 250 patients of other HLA types…
-
11 months ago benzinga.com
Greenwich Lifesciences Announces Phase 3 FLAMINGO-01 Trial Of GLSI-100, An Immunotherapy To Prevent Breast Cancer Recurrences, Has Achieved A Major Milestone By Screening Over 1,000 Patients
Flamingo-01 Progress to DateThe Company has achieved a major milestone by screening over 1,000 patients in Flamingo-01, continuing its screening rate of approximately 150 patients per quarter or the…
-
1 year ago benzinga.com
Greenwich LifeSciences Strengthens European Presence As Flamingo-01 Clinical Trial Adds Belgium To Nine Approved Countries
The Company's application to European regulators has been formally approved, adding Belgium as an approved country in FLAMINGO-01 in addition to Spain, France, Germany, Italy, Poland, Romania,…
-
1 year ago benzinga.com
Greenwich LifeSciences Takes Fight Against Breast Cancer Recurrence Global with Trial Expansion into Portugal
Greenwich LifeSciences, Inc. (NASDAQ:GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01, which is evaluating GLSI-100, an…
-
1 year ago benzinga.com
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
-
1 year ago benzinga.com
The FDA Has Granted Fast Track Designation To Greenwich Lifesciences' GLSI-100 In HLA-A*02 Patient Population
Greenwich LifeSciences, Inc. (NASDAQ:GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01, which is evaluating GLSI-100, an…
-
1 year ago benzinga.com
Greenwich LifeSciences Cuts Costs by Bringing Breast Cancer Trial Management In-House
Greenwich LifeSciences, Inc. (NASDAQ:GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01, which is evaluating GLSI-100, an…
-
1 year ago benzinga.com
Greenwich LifeSciences Expands Phase III Breast Cancer Trial Into Romania After Regulatory Green Light
Greenwich LifeSciences, Inc. (NASDAQ:GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01, which is evaluating GLSI-100, an…
-
1 year ago benzinga.com
Greenwich LifeSciences Q1 EPS $(0.25) Down From $(0.19) YoY
Greenwich LifeSciences (NASDAQ:GLSI) reported quarterly losses of $(0.25) per share. This is a 31.58 percent decrease over losses of $(0.19) per share from the same period last year.
-
1 year ago benzinga.com
12 Health Care Stocks Moving In Thursday's Pre-Market Session
12 Health Care Stocks Moving In Thursday's Pre-Market Session
-
1 year ago benzinga.com
HC Wainwright & Co. Maintains Buy on Greenwich LifeSciences, Raises Price Target to $39
HC Wainwright & Co. analyst Yi Chen maintains Greenwich LifeSciences (NASDAQ:GLSI) with a Buy and raises the price target from $38 to $39.
-
1 year ago benzinga.com
Greenwich Lifesciences Provides Update On Its Phase III Clinical Trial, Flamingo-01, Which Is Evaluating GLSI-100, An Immunotherapy To Prevent Breast Cancer Recurrences
Flamingo-01 Progress to Date & Future PlansThe Company recently confirmed that the preliminary HLA prevalence, safety, and immune response data in FLAMINGO-01 patients is trending as expected in both…
-
1 year ago benzinga.com
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
-
1 year ago benzinga.com
Greenwich Lifesciences Announces Immune Response Data From FLAMINGO-01 Phase 3 Clinical Trial
FLAMINGO-01 Immune Response Data SummaryThe Company has analyzed the preliminary immune response data from FLAMINGO-01. Immune response data in both the HLA-A*02 treated and placebo arms and the…
-
1 year ago benzinga.com
Greenwich LifeSciences Announced An Update On FLAMINGO-01 Open Label Safety Data
FLAMINGO-01 Data Safety Monitoring Board (DSMB)The FLAMINGO-01 DSMB met twice in 2024, most recently in December 2024, and recommended to continue the study as is without modification. No serious…
-
1 year ago benzinga.com
HC Wainwright & Co. Reiterates Buy on Greenwich LifeSciences, Maintains $38 Price Target
HC Wainwright & Co. analyst Yi Chen reiterates Greenwich LifeSciences (NASDAQ:GLSI) with a Buy and maintains $38 price target.